Evolus, Inc.
General ticker "EOLS" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $639.1M (TTM average)
Evolus, Inc. does not follow the US Stock Market performance with the rate: -15.6%.
Estimated limits based on current volatility of 2.3%: low 6.60$, high 6.91$
Factors to consider:
- Total employees count: 332 (+21.6%) as of 2024
- US accounted for 95.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Significant losses, Capital raising, Geopolitical risks, Strategic risks and growth management, Key executive dependency
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.12$, 15.55$]
- 2025-12-31 to 2026-12-31 estimated range: [4.68$, 12.29$]
Financial Metrics affecting the EOLS estimates:
- Negative: with PPE of -28.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.64 <= 0.33
- Positive: Industry inventory ratio change (median), % of -1.41 <= -0.15
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 2.75 <= 3.41
- Positive: Inventory ratio change, % of -0.86 <= -0.75
- Negative: negative Net income
- Positive: -4.48 < Investing cash flow per share per price, % of -0.71
Short-term EOLS quotes
Long-term EOLS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $142.86MM | $197.83MM | $259.10MM |
| Operating Expenses | $208.19MM | $247.06MM | $293.51MM |
| Operating Income | $-65.33MM | $-49.23MM | $-34.41MM |
| Non-Operating Income | $-8.99MM | $-12.28MM | $-15.35MM |
| Interest Expense | $9.10MM | $13.83MM | $18.73MM |
| R&D Expense | $6.74MM | $15.43MM | $9.17MM |
| Income(Loss) | $-74.32MM | $-61.51MM | $-49.76MM |
| Taxes | $0.10MM | $0.18MM | $0.66MM |
| Profit(Loss)* | $-74.41MM | $-61.69MM | $-50.42MM |
| Stockholders Equity | $18.50MM | $-20.69MM | $5.52MM |
| Inventory | $18.85MM | $11.00MM | $12.16MM |
| Assets | $177.98MM | $189.00MM | $232.57MM |
| Operating Cash Flow | $-84.91MM | $-34.01MM | $-18.00MM |
| Capital expenditure | $2.94MM | $1.63MM | $1.47MM |
| Investing Cash Flow | $-2.94MM | $-1.63MM | $-4.82MM |
| Financing Cash Flow | $-4.15MM | $44.64MM | $47.41MM |
| Earnings Per Share** | $-1.33 | $-1.08 | $-0.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.